Penalty Amount
$7,400,000,000
Connecticut Attorney General William Tong announced that Purdue Pharma will dissolve as the company’s bankruptcy concludes and a $7.4 billion settlement with Purdue and the Sackler family takes effect. The settlement permanently bars the Sacklers from selling opioids in the U.S., directs funds to addiction treatment and prevention, and requires the release of over 30 million documents related to Purdue’s opioid business. Connecticut is expected to receive $64 million from the settlement, with first payments anticipated in fall 2026.
Purdue Pharma will dissolve, with its manufacturing operations transferred to Knoa Pharma LLC, which is barred from marketing opioids and subject to an independent monitor. The Sackler family is permanently banned from selling opioids in the U.S., and must pay over $1.5 billion immediately, with additional payments totaling $1.4 billion through 2029, while Purdue pays $900 million immediately, totaling $7.4 billion in settlement funds distributed to states, municipalities, and victims over 15 years. Purdue and the Sacklers must also publicly release over 30 million documents related to their opioid business.
This enforcement action involves opioid marketing violations and bankruptcy proceedings, with no privacy-related violations or remedies. No privacy-related contract clauses (e.g., data processing, breach notification, consent) require review based on this action. In-house teams in the pharmaceutical industry should review vendor and marketing agreements for compliance with opioid regulations, but this action has no implications for privacy-related vendor, customer, or employee agreements.
Entity
Purdue Pharma
Industry
Healthcare"Purdue Pharma"
"$7.4 billion settlement"
"05/01/2026"
"Connecticut"
"settlement"
"permanently bars the Sacklers from selling opioids in the U.S."
$7.4B
New York Attorney General Letitia James announced the shutdown of opioid manufacturer Purdue Pharma as part of a $7.4 billion settlement with a bipartisan coalition of 54 other state attorneys general. The Sackler family, former owners of Purdue, are permanently barred from selling opioids in the U.S. and have no involvement in Knoa Pharma, the new public benefit corporation replacing Purdue. Purdue was sentenced on criminal charges related to its role in the opioid crisis on April 28, 2026, with the new entity operating under strict oversight and excess revenue funding opioid abatement efforts.
$7.4B
The U.S. Bankruptcy Court confirmed a $7.4 billion settlement between Purdue Pharma, the Sackler Family, and 55 attorneys general to resolve claims over the opioid crisis. Connecticut will receive up to $64 million for treatment, prevention, and victim support. The settlement bars the Sacklers from selling opioids and requires public disclosure of documents.
Connecticut Attorney General William Tong joined a coalition of states and local governments in filing suit against NHTSA over its rule weakening fuel economy standards for new passenger cars and light trucks. The lawsuit alleges the rule violates the agency’s statutory mandate and the Administrative Procedure Act; no penalty or final remedy is reported.
Connecticut Attorney General William Tong joined a multistate coalition suing the EPA over its repeal of greenhouse gas pollution limits for power plants and separately filed a notice of intent to sue over regulation of existing gas plants. The coalition asks the court to overturn the repeal and restore the protections; the release reports no monetary penalty or final order.
$400.0M
Connecticut Attorney General William Tong announced a $400 million settlement with Sandoz Inc. and Fougera Pharmaceuticals Inc. resolving allegations that the generic drug manufacturers conspired to inflate prices, limit competition, and restrain trade. The settlement includes consumer restitution and injunctive reforms; court approval was being sought.
Connecticut Attorney General William Tong joined a coalition of 21 attorneys general in submitting a comment letter opposing a DHS rule that allows certain affirmative asylum applications to be referred to removal proceedings without an asylum officer interview. The coalition argues the rule violates federal law and harms asylum seekers, including unaccompanied children; this was a policy opposition letter, not a privacy enforcement action.